Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C
NCT00275548Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2004
- Primary completion
- Jun 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Proportion of patients who experienced histologically confirmed recurrence of HCV at 120 weeks. Started Jul 2004; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00275548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275548.